Product Description
Mechanisms of Action: CCL2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Sclerosis, Relapsing-Remitting|Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00239655 |
MK0812-003 | P2 |
Terminated |
Multiple Sclerosis, Relapsing-Remitting |
2005-12-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00542022 |
MK0812-008 | P2 |
Completed |
Arthritis, Rheumatoid |
2005-05-01 |
2022-05-04 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/25/2024 |
PubMed |
Identification of effective CCR2 inhibitors for cancer therapy using humanized mice. |
|
03/01/2020 |
PubMed |
In situ crystallography as an emerging method for structure solution of membrane proteins: the case of CCR2A. |